WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003002739) ANTISENSE OLIGONUCLEOTIDE AGAINST HUMAN ACETYLCHOLINESTERASE (ACHE) AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/002739    International Application No.:    PCT/IL2002/000411
Publication Date: 09.01.2003 International Filing Date: 23.05.2002
IPC:
A61K 38/00 (2006.01), C12N 15/11 (2006.01)
Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Hi Tech Park The Hebrew University of Jerusalem Edmond J Safra Campus, Givat Ram P. O. Box 39135 91390 Jeruslem (IL) (For All Designated States Except US).
SOREQ, Hermona [IL/IL]; (IL) (For US Only)
Inventors: SOREQ, Hermona; (IL)
Agent: LUZZATTO & LUZZATTO; P.O. Box 5352 84152 Beer-Sheva (IL)
Priority Data:
143379 24.05.2001 IL
Title (EN) ANTISENSE OLIGONUCLEOTIDE AGAINST HUMAN ACETYLCHOLINESTERASE (ACHE) AND USES THEREOF
(FR) OLIGONUCLEOTIDE ANTISENS CONTRE L'ACETYLCHOLINESTERASE HUMAINE (ACHE) ET UTILISATIONS ASSOCIEES
Abstract: front page image
(EN)The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
(FR)L'invention concerne un oligonucléotide antisens ciblant la zone de codage de l'acétylcholinestérase humaine (AChE), qui supprime de manière sélective l'isoforme AchE-R de l'enzyme. L'oligonucléotide antisens peut être utilisé dans le traitement et/ou la prévention de troubles neuromusculaires, de préférence myasthenia gravis. En outre, il peut pénétrer la barrière hémato-encéphalique et détruire l'AchE-R à l'intérieur des neurones du système nerveux central, tout en servant de porteur permettant de transporter des molécules à travers ladite barrière hémato-encéphalique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)